Ascentage Pharma Group International
(NASDAQ) AAPG
Ascentage Pharma Group International Financials at a Glance
Market Cap
$2.35B
Revenue (TTM)
$1.55B
Net Income (TTM)
$1.64B
EPS (TTM)
$-1.94
P/E Ratio
-13.04
Dividend
$0.00
Beta (Volatility)
0.80 (Low)
Dividend
$0.00
Beta (Volatility)
0.80 (Low)
Price
$25.33
Volume
625.72
Open
$24.81
Price
$25.33
Volume
625.72
Open
$24.81
Previous Close
$25.33
Daily Range
$24.81 - $25.33
52-Week Range
$18.52 - $48.45
Dividend
$0.00
Beta (Volatility)
0.80 (Low)
Price
$25.33
Volume
625.72
Open
$24.81
Previous Close
$25.33
Daily Range
$24.81 - $25.33
52-Week Range
$18.52 - $48.45
AAPG News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ascentage Pharma Group International
Industry
Biotechnology
Sector
Health CareEmployees
567
CEO
Da Jan Yang, MD, PhD
Website
www.ascentage.comHeadquarters
Suzhou, 215000, CN
AAPG Financials
Key Financial Metrics (TTM)
Gross Margin
84%
Operating Margin
-2%
Net Income Margin
-2%
Return on Equity
-153%
Return on Capital
-51%
Return on Assets
-31%
Earnings Yield
-7.67%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.35B
Shares Outstanding
92.78M
Volume
625.72
Short Interest
0.00%
Avg. Volume
3.01K
Financials (TTM)
Gross Profit
$426.75M
Operating Income
$1.18B
EBITDA
$1.10B
Operating Cash Flow
$111.36M
Capital Expenditure
$24.29M
Free Cash Flow
$135.65M
Cash & ST Invst.
$2.47B
Total Debt
$1.98B
Ascentage Pharma Group International Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$334.13M
+321.4%
Gross Profit
$265.45M
+296.8%
Gross Margin
79.44%
N/A
Market Cap
$2.35B
N/A
Market Cap/Employee
$4.14M
N/A
Employees
567
N/A
Net Income
$639.96M
-22.3%
EBITDA
$598.95M
-21.6%
Quarterly Fundamentals
Net Cash
$490.68M
+167.6%
Accounts Receivable
$253.10M
+54.8%
Inventory
$28.64M
+77.1%
Long Term Debt
$757.72M
-35.7%
Short Term Debt
$1.22B
+98.5%
Return on Assets
-31.03%
N/A
Return on Invested Capital
-51.46%
N/A
Free Cash Flow
$0.00
+100.0%
Operating Cash Flow
$0.00
+100.0%